We rarely encounter patients with proptosis, however, it is known that inflammation and extension of paranasal sinus tumors may cause this condition. We should consider the diseases that may cause proptosis to facilitate the diagnosis. Recently, we treated proptosis in 2 cases, one with inflammatory myofibroblastic tumor (IMT) and the other with malignant lymphoma. As these 2 diseases show various clinical features and these features frequently overlap, it is difficult to differentiate between IMT and malignant lymphoma without pathological examinations. In this study, we review the relevant literature reports and discuss the difficulties in establishing a clinicopathological diagnosis and present a slight distinction in magnetic resonance imaging.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.anl.2009.11.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Eight patients with inflammatory myofibroblastic tumor treated with rigid bronchoscopy.
BMC Pulm Med
January 2025
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.
Background: Pulmonary inflammatory myofibroblastic tumor (IMT) accounts for 0.04-0.7% of all lung tumors, and endobronchial IMT accounts for only 10% of all pulmonary IMTs.
View Article and Find Full Text PDFRobust circulating microRNA signature for the diagnosis and early detection of pancreatobiliary cancer.
BMC Med
January 2025
Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan.
Background: A new circulating biomarker superior to carbohydrate antigen 19-9 (CA19-9) is needed for diagnosing pancreatobiliary cancer (PBca). The aim of this study was to identify serum microRNA (miRNA) signatures comprising reproducible and disease-related miRNAs.
Methods: This multicenter study involved patients with treatment-naïve PBca and healthy participants.
The clinicopathologic features of uterine inflammatory myofibroblastic tumor: A case report.
Medicine (Baltimore)
January 2025
Department of Obstetrics, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Rationale: Inflammatory myofibroblastic tumor (IMT) is a rare soft tissue neoplasm with low malignant potential. These patients present with a certain probability of malignant potential. The management of IMT has not been standardized, especially for the patients with fertility needs.
View Article and Find Full Text PDFIntestinal icrobiota Transplant Prior to llogeneic tem Cell ransplant (MAST) trial: study protocol for a multicentre, double-blinded, placebo-controlled, phase IIa trial.
BMJ Open
December 2024
Centre for Haematology, Department of immunology and inflammation, Faculty of Medicine, Imperial College London, London, UK.
Introduction: Lower diversity of the gut microbiome prior to allogeneic haematopoietic cell transplantation (HCT) correlates with reduced survival after the intervention. Most patients undergoing HCT for a haematological malignancy have previously received intensive chemotherapy, resulting in prolonged neutropenic episodes requiring broad-spectrum antibiotics; use of these has been linked to reduced microbiome diversity. Intestinal microbiota transplant (IMT) is a novel treatment approach that restores this diversity.
View Article and Find Full Text PDFCoexisting growing teratoma syndrome and gliomatosis peritonei following ovarian immature teratoma: a case report and literature review.
Turk J Med Sci
December 2024
Department of Obstetrics and Gynecology, Faculty of Medicine, University of Health Sciences, Ankara, Turkiye.
Growing teratoma syndrome (GTS) is characterized by a reduction in serum tumor markers despite the growth of a benign mature teratomatous mass following chemotherapy for germ cell tumors. Gliomatosis peritonei (GP) typically accompanies ovarian teratomas, marked by the dissemination of mature glial tissue across the peritoneum. The concurrent presence of GTS and GP after treatment for ovarian immature teratoma (IMT) is notably rare, with approximately 20 reported cases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!